Medipal Holdings Corporation · TSE:7459
Medipal — Q1 FY2025 Earnings Presentation
11 slides from Medipal's earnings presentation, Aug 1, 2024
Slide 1: Financial Results for the First Quarter Ended Jun. 30, 2024
Financial Results for the First Quarter Ended Jun. 30, 2024 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being and to enhance its corporate value. August. 1, 2024 Forward-Lookin
Slide 2: Performance Summary for the First Quarter Ended Jun. 30, 2024
Performance Summary for the First Quarter Ended Jun. 30, 2024 The MEDIPAL Group started the first quarter strong, achieving increases in sales, operating profit and ordinary profit. Continue to focus on strategic investments for sustainable growth ■Prescription Pharmaceutical Wholesale Business Ac
Slide 3: Consolidated Statements of Income
Consolidated Statements of Income Results for Results for YoY (\ billion) the 1Q Ended the 1Q Ended Rate of Change Change Jun. 30, 2023 Jun. 30, 2024 Net Sales 886.7 909.3 +22.5 +2.5% Gross Profit 59.3 62.5 +3.2 +5.5% (Gross Profit Ratio) （6.69％) （6.88％) (＋0.19pp) SG&A Expenses 46.9 49.3 +2.3 +5.1%
Slide 4: Consolidated Statements of Income [Change Factors from FY2023/1Q]
Consolidated Statements of Income [Change Factors from FY2023/1Q] Amount YoY Change Change factors from FY2022 All business segments* exceeded the sales YoY Prescription Pharmaceutical Wholesale Business:+2.2% ¥909.3 billion +¥22.5 billion Cosmetics, Daily Necessities and OTC Pharmaceutical Whol
Slide 5: Prescription Pharmaceutical Wholesale Business (MEDICEO Business)
Prescription Pharmaceutical Wholesale Business (MEDICEO Business) Although there were negative impacts from drug price revisions and a decrease in demand for COVID-19 treatment drugs, the market grew due to an increase in doctor consultations as a result of the transition to Category 5 COVID-19. In
Slide 6: Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business (PALTAC Business)
Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business (PALTAC Business) Sales expansion measures and profit improvement measures were successful, ensuring increased sales and profits (\ billion) Results for the 1Q Ended Results for the 1Q Ended YoY Rate of Net Sales ¥302.9 billion +
Slide 7: Animal Health Products and Food Processing Raw Materials Wholesale and Related Business
Animal Health Products and Food Processing Raw Materials Wholesale and Related Business (AGRO・ FOOD Business) Although sales grew, operating profit decreased due to an increase in SG&A Expenses to strengthen business activities. Results for Results for YoY Rate of (\ billion) the 1Q Ended the 1Q End
Slide 8: Appendix
Appendix P.9 Acquiring all shares of PreMedica Inc. P.10 Investment in MNES Inc. (through MEDIPAL Innovation Fund) ※Reprinted from the financial results presentation for the fiscal year ending March 31,2024 Copyright © 2024 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 8
Slide 9: Acquiring all shares of PreMedica Inc.
2027 MEDIPAL Medium-Term Vision Growth Strategies Expansion of Preventive and Pre-Disease Business Acquiring all shares of PreMedica Inc. ■ Responding to the shift in medical care from “treatment” to “preventive and pre-disease” ■ Expecting synergistic effects since MEDIPAL's growth strategy and Pri
Slide 10: Investment in MNES Inc. (through MEDIPAL Innovation Fund)
Appendix② Investment in MNES Inc. (through MEDIPAL Innovation Fund) Both companies will create synergies in anticipation of an era when medical information will be fully cloud-based. ■ Undertakes third-party allotment capital increase of MNES Inc. which develops medical support cloud services, etc.
Slide 11: Contributing to people's health and the advancement of society through creation of value in distribution
Contributing to people’s health and the advancement of society through creation of value in distribution